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The present study was undertaken with an aim to formulate, develop and evaluate
gastroretentive floating tablets of an antidepressant drug, Venlafaxine HCl (hydrochlo-
ride), which release the drug in a sustained manner over a period of 24 h. Three different
hydrophobic retardants namely hydrogenated cottonseed oil, carnauba wax, cetyl alcohol
and a hydrophilic polymer Methocel® (hydroxy propyl methyl cellulose (HPMC)) K15M
were used in different combinations at different ratios for the preparation of tablets. The
tablets were prepared by Hot Melt or Thermoplastic granulation method and evaluated
for tablet thickness, hardness, weight variation, friability, floating lag time and in vitro
drug release. Formulation F8 with hydrophilic polymer (Methocel® K15M) and hydro-
phobic retardant (carnauba wax) in the ratio 1:2.6 (approx.) was considered as an opti-
mized formulation. The optimized formulation showed satisfactory sustained drug
release and remained buoyant on the surface of the medium for more than 24 h and its
release profile was comparable with the marketed formulation (VENTAB-XL 37.5). It can
also be concluded that floating drug delivery system of Venlafaxine HCl can be suc-
cessfully formulated as an approach to increase gastric residence time and thereby
improving its bioavailability.
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Oral sustained drug delivery system is complicated by limited
gastric residence time. Rapid gastrointestinal transit can
prevent complete drug release in the absorption zone and
reduce the efficacy of administered dose, since the majority
of drugs are absorbed in stomach or the upper part of small
intestine (Choi et al., 2008; Mahant and Nasa, 2011). Floating
drug delivery offers several applications for drugs having
poor bioavailability because of the narrow absorption win-
dow in the upper part of the gastrointestinal tract. It retains
the dosage form at the site of absorption and thus enhances
the bioavailability (Kaza et al., 2009). Venlafaxine HCl is a
unique antidepressant, and is referred to as a serotonin,
norepinephrine-dopamine reuptake inhibitor (Keith, 2006).
Venlafaxine HCl is a highly water soluble drug (Nidadavolu,
2014). Venlafaxine HCl and its active metabolite, o-des-
methyl venlafaxine (ODV) inhibit the neuronal uptake of
norepinephrine, serotonin and to a lesser extent dopamine
(Ric et al., 1991). Hence it lacks the adverse anticholinergic,
sedative and cardiovascular effects of tricyclic antidepres-
sants (Simona and Aguiar, 2004) .The steady state half-lives
of Venlafaxine HCl and ODV are 5 and 11 h, respectively,
necessitating the administration 2 or 3 times daily so as to
maintain adequate plasma levels of drug (Troy et al., 1995).
The half-life of Venlafaxine HCl is relatively short, and,
therefore, patients are directed to adhere to strict medication
routine, avoiding missing a dose. Even a single missed dose
can result in the withdrawal symptoms (Parker and
Blennerhassett, 1998). In such case the formulation
releasing the drug in sustained manner will aid the patient to
adhere to strict medication routine by avoiding the need to
take the dosage form 2 or 3 times daily. The use of sustained
release formulation is associated with less nausea and
dizziness (Olver et al., 2004).
The objective of the present research work was to pro-
vide gastroretentive formulation that will provide once-
daily, sustained release dosage form. The swellable hydro-
philic polymer Methocel® K15M (hydroxy propyl methyl
cellulose) and hydrophobic retardants like hydrogenated
cottonseed oil, carnauba wax and cetyl alcohol were tried at
different ratios to prepare various formulations of Ven-
lafaxine HCl.2. Materials and methods
Venlafaxine hydrochloride was obtained as a gift sample
from Amoli Organics Pvt. Ltd., Vadodara, India. Carnauba
Wax, cetyl alcohol and Talc were procured from SD Fine
Chemicals, Mumbai. Hydrogenated cottonseed oil was ob-
tained as gift sample from Zhaveri Pvt. Ltd., Mumbai.
Methocel® K15M (hydroxy propyl methyl cellulose) was ob-
tained as gift sample from Colorcon Asia Pvt., Ltd. Goa, India.
All other excipients and chemicals used were of analytical
grade. VENTAB-XL 37.5 (Batch no. DN3651) was procured
from the local market.2.1. Drugeexcipients interaction study and
identification
2.1.1. Fourier transform infrared spectroscopy (FTIR)
An infrared spectrum of pure drug, mixture of drug with each
retardant and physical mixture of optimized formulation was
recorded using SHIMADZU FTIR Spectrophotometer. The
scanning range was 500e4000 cm1 and the IR spectra of
samples were obtained using KBr disc method. Any change in
spectrum pattern of drug due to presence of polymers was
investigated to identify any chemical interaction.
2.1.2. Differential scanning calorimetry (DSC)
The possibility of drugeexcipient interaction was further
investigated by differential scanning calorimetry. DSC anal-
ysis was performed using SIECKO SII EXSTAR DSC 6220 Soft-
ware on 10 mg sample. Samples were heated in aluminum
pan at a rate of 10 C/min. within a 30e305 C temperature
range under a nitrogen flow of 10 ml/min. Alumina was used
as a reference.
2.1.3. UV spectroscopy (determination of l (lambda)max)
The stock solution (1000 mg/ml) of Venlafaxine HCl was pre-
pared in distilled water. This solution was appropriately
diluted with distilled water to obtain a concentration of 3 mg/
ml. The UV spectrum was recorded in the range of
200e400 nm on Shimadzu double beam UVevisible spectro-
photometer. The same procedure was carried out in 0.1 N HCl
(hydrochloric acid, pH 1.2). The spectrum and wavelength of
maximum absorption were recorded.2.2. Preparation of standard curve
The stock solution (1000 mg/ml) of Venlafaxine HCl was pre-
pared in 0.1 N HCl. From this 30 mg/ml second stock solution
was made. This was withdrawn as 1, 2, 3, 4, 5, 6, 7, 8, 9 and
10 ml and diluted each with 0.1 N HCl (pH 1.2) to obtain con-
centrations of 3, 6, 9, 12, 15, 18, 21, 24, 27 and 30 mg/ml. The
absorbance of these solutions were measured at 225 nm
against blank i.e. 0.1 N HCl. Same procedure was followed for
the preparation of standard curve of distilled water. The co-
efficient of correlation and equation for the line are
determined.2.3. Preparation of Venlafaxine HCl effervescent tablet
Effervescent floating tablets, each containing 37.5 mg Ven-
lafaxine HCl were prepared by melt granulation method. The
composition of various formulations is shown in Table 1.All
the ingredients except wax were passed through sieve 40. The
wax/oil were melted in porcelain dish on hot plate and drug
was added to it. Then to this mixture other sieved ingredients
except talc were added. The resultant mixture was allowed to
solidify at room temperature and then passed through sieve
16 to form granules. The granules were lubricated by adding
talc extra granularly. The lubricated granules were then
compressed into a tablet using 10 mm standard flat-face
punches on single punch tableting machine (Royal Artist Pvt.
Table 1 e Formulation of effervescent floating tablets of Venlafaxine HCl.
Ingredients mg/tablet F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
Venlafaxine hydrochloride 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5 37.5
Hydrogenated cottonseed oil 80 e e 120 e e 160 e e 200 e e
Carnauba wax e 80 e e 120 e e 160 e e 200 e
Cetyl alcohol e e 80 e e 120 e e 160 e e 200
HPMC K15M 142 142 142 102 102 102 62 62 62 22 22 22
NaHCO3 50 50 50 50 50 50 50 50 50 50 50 50
Talc. 3 3 3 3 3 3 3 3 3 3 3 3
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lafaxine HCl and total tablet weight was kept constant at
312.5 mg .The prepared tablets were evaluated for below
mentioned parameters.2.4. Pre-compression evaluation
The granules were evaluated for flow property i.e. angle of
repose, bulk density, tapped density, compressibility index
(Carr's index) and Hausner's ratio using standard procedures
(Indian Pharmacopoeia, 1996; Lachman et al., 1990).2.5. Post-compression evaluation
The prepared tablets were evaluated for their physical pa-
rameters like hardness, thickness, weight variation, friability
and drug content (Indian Pharmacopeia, 1996; Lachman et al.,
1990).
To study weight variation, twenty tablets of each formu-
lation were weighed using an electronic balance and the test
was performed. Thickness and diameter of tablets was
determined using Vernier caliper. Ten tablets from each batch
were used, and their average values calculated. Hardness of
ten tablets of each formulation was determined using Mon-
santo hardness tester.
Friability of twenty tabletswas determined using the Roche
friabilator. This test subjects a number of tablets to the com-
bined effect of shock and abrasion by utilizing a plastic
chamber which revolves at speed of 25 rpm, dropping the
tablets to a distance of 6 inches in each revolution. A sample of
pre-weighed tablets was placed in Roche friabilator, which
was then operated for 100 revolutions for 4 min. The tablets
were then dusted and reweighed.
Ten tablets containing Venlafaxine HCl were crushed to a
fine powder. A quantity equivalent to 100 mg of Venlafaxine
hydrochloride was added into 100 ml volumetric flask and
dissolved in 0.1 N HCl (pH 1.2). After suitable dilutions the
absorbance was determined by UV spectrophotometer (Shi-
madzu) at 225 nm against blank. The drug content was
calculated by using calibration curve (Vasanth et al., 2012).
The in vitro buoyancy test was determined by floating lag
time, as per the method described by (Rosa et al., 1994; Abdul
and Lila, 2011). The tablets were placed in a 100-ml beaker
containing 0.1 N HCl (pH 1.2). The time required for the tablet
to rise to the surface and float was determined as floating lag
time (FLT) and the time for which the tablet constantly floats
on the surface of the medium (duration of floating), was
measured.The release rate of Venlafaxine HCl floating tablets was
determined using USP Type II Apparatus (Paddle Type). The
dissolution test was performed, using 900 ml of 0.1 N HCl, at
37 ± 0.5 C at 50 rpm for 24 h. A 5 ml sample was withdrawn
from the dissolution apparatus at specified time and the
samples were replaced with fresh dissolution medium. The
samples were filtered through a 0.45 mmmembrane filter and
sufficiently diluted. Absorbance of these solutions were
measured at 225 nm using UVevisible spectrophotometer
(Vasanth et al., 2012). The marketed formulation VENTAB-XL
37.5 mg was also evaluated for in vitro drug release.
The floating tablets were weighed individually (designated
asW0) and placed separately in glass beaker containing 200ml
of 0.1 N HCl and incubated at 37 C ± 1 C. At regular 1 h time
intervals until 4 h the floating tablets were removed from
beaker, and the excess surface liquid was removed carefully
using the tissue paper. The swollen floating tablets were then
re-weighed (Wt), and % swelling index (SI) was calculated
using the following formula (Lodhiya et al., 2009).
SI ð%Þ ¼ ðWt W0=W0Þ  100 (1)
where, Wt ¼ weight of tablet at time t, W0 ¼ initial weight of
tablet.
2.6. Kinetic analysis of release data
The obtained dissolution data was fitted to zero order, first
order, Higuchi and KorsmeyerePeppas equations to under-
stand the rate and mechanism of drug release from the pre-
pared formulations. The correlation coefficients values were
calculated and used to find the fitness of the data.
Zero order equation (Brahamankar and Jaiswal, 2009),
Qt ¼ Q0 þ K0t (2)
describes the systems where the drug release rate is inde-
pendent of concentration of the dissolved substance, where,
Q0 ¼ initial amount of drug, Qt ¼ cumulative amount of drug
release at time t, K0¼ zero order release constant, t¼ time in h.
First order release equation (Brahamankar and Jaiswal,
2009)
Log Qt ¼ Log Q0 þ Kt=2:303 (3)
the drug release rate depends on its concentration, where,
Q0 ¼ initial amount of drug, Qt ¼ cumulative amount of drug
release at time t, K ¼ first order release constant, t ¼ time in h.
Higuchi release equation (Higuchi, 1963),
Q ¼ KHt1=2 or Mt=Mo ¼ Kt1=2 (4)
Fig. 1 e UV spectrum of Venlafaxine HCl in 0.1 N HCl.
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diffusion mechanism. Q ¼ cumulative amount of drug release
at time t, KH ¼ Higuchi constant, t ¼ time in h.
KorsmeyerePeppas equation (Korsmeyer et al., 1983)
F ¼ ðMt=M∞Þ ¼ Kmtn (5)
which describes the drug release from a polymeric system,
where F ¼ fraction of drug released at time t, Mt ¼ amount of
drug released at time t, M∞ ¼ total amount of drug in dosage
form, Km¼ kinetic constant, n¼ diffusion or release exponent,
t ¼ time in h.
2.7. Statistical analysis
In-vitro drug release profile of Venlafaxine HCl sustained
release tablets was compared with drug release profile of
marketed formulation VENTAB-XL 37.5 tablets under similar
experimental conditions. The data obtained from in vitro drug
release was used to determine the similarity factor and
dissimilarity factor betweenmarketed product and optimized
formulation. The similarity factor (f2) and dissimilarity factor
(f1) were calculated using the formulas (Shah et al., 2011)
f1 ¼
½PjRt  Ttj
½PRt

 100; where t ¼ 1 to n (6)
f2 ¼ 50 log
("
1þ 1
n
Xn
t¼1
h
ðRt  TtÞ2
i0:5#
 100
)
(7)
where n is number of time points, Rt and Tt are dissolution of
reference and test products at time t respectively. In general, f1
values lower than 15 (0e15) and f2 values higher than 50
(50e100) show the similarity of the dissolution profiles.
The Independent-samples t-test was also applied to check
similarity between the optimized formulation (F8) and mar-
keted product. Differences were considered to be statistically
significant at p < 0.05 (Kavita et al., 2010).
2.8. Stability study
The optimized formulation (F8) packed in silver foil and sub-
jected to stability studies at 40 C ± 2 C/75 ± 5% RH. Sample
was withdrawn at predetermined time intervals of 0 (initial),
30, 60 and 90 days. Tablet was evaluated for the different
physicochemical parameters viz. appearance, weight varia-
tion, thickness, hardness, friability, drug content and in vitro
release.Fig. 2 e Calibration curve of Venlafaxine HCl in 0.1 N HCl.3. Results and discussion
3.1. Drugeexcipients interaction and identification
The wavelength of maximum absorbance was obtained at
225 nm (Fig. 1). The calibration curve was found to be linear in
the range of 3e30 mg/ml and straight line equation was ob-
tained having the regression coefficient value of 0.9955 (Fig. 2).
FTIR spectrum of Venlafaxine HCl showed a characteristic
stretching band of OeH at 3350.35 cm1, aromatic C]H
stretching at 1614.42 cm1, CeO stretching at 1514.12 cm1and CeN stretching at 1178.51 cm1, CeOeC stretching at
1043.49 cm1, C]O stretching at 1732.08 cm1 wavenumber
(Fig. 3). These characteristic stretching bands were slightly
varied after pre-formulation study, revealing no chemical
interaction (Figs. 4e7).
DSC thermo gram showed a sharp endothermic peak at
214.7 C which is corresponding to melting point of the drug
(Fig. 8). Pre-formulation study indicated the slight broadening
and shifting of endothermic peak due to melting effect of
hydrophilic polymers and hydrophobic retardants (Fig. 9)
(Bagdiya et al., 2012).3.2. Formulation development
The concentration of all the three selected hydrophobic re-
tardants (carnauba wax, hydrogenated cottonseed oil and
cetyl alcohol) was decided on trial and error basis. Sodium
bicarbonate was incorporated as a gas-generating agent. The
trial batches were conducted to finalize the concentration of
sodium bicarbonate. Talc was used as glidant to improve the
flow of the granules. FTIR study showed that all the re-
tardants/excipients used were compatible with Venlafaxine
HCl.
Nanjwade et al. reported that the use of a hydrophobic
carrier along with a hydrophilic polymer effectively controls
the initial rapid release of a highly water soluble drug such as
Venlafaxine HCl. Hot melt granulationmethod (also known as
Fig. 3 e FTIR of pure Venlafaxine HCl.
Fig. 4 e FTIR of combination of Venlafaxine HCl and carnauba wax.
Fig. 5 e FTIR of combination of Venlafaxine HCl and hydrogenated cottonseed oil.
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Fig. 6 e FTIR of combination of Venlafaxine HCl and cetyl alcohol.
Fig. 7 e FTIR of physical mixture of optimized formulation (F8).
Fig. 8 e DSC of pure Venlafaxine HCl.
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tive in achieving this than the direct compression method
(Nanjwade et al., 2011).
From the literature survey it was evident that Methocel®
K15M is a good polymer for floating drug delivery system as it
is a matrix forming and low density polymer (Lakshmaiah
et al., 2014). Hydrophobic melt able materials impart suffi-
cient integrity to the tablets (Ghada and Ramadan, 2012).
Lipids/waxes are considered as an alternative to polymers in
the design of sustained drug delivery systems due to their
advantages such as the low melt viscosity (thus avoiding the
need of organic solvents for solubilization), absence of toxic
impurities such as residual monomer catalysts and initiators,
potential biocompatibility and biodegradability (Senthil et al.,
2011).
Reza et al., has stated that the drug particles present on the
surface of a matrix system were initially released into the
surrounding media generating many pores and cracks which
Fig. 9 e DSC of physical mixture of optimized formulation (F8).
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nels within the matrix in the case of a water soluble drug like
Venlafaxine HCl. HPMC tablets upon contact with the disso-
lution medium swell due to the disruption of hydrogenTable 2 e Pre-compression evaluation.
Formulation
code
Angle of
reposea
Bulk density
(g/ml)
F1 28.24 ± 0.13 0.408 ± 0.13
F2 27.08 ± 0.02 0.404 ± 0.17
F3 30.11 ± 0.08 0.416 ± 0.05
F4 29.25 ± 0.11 0.408 ± 0.01
F5 28.78 ± 0.14 0.422 ± 0.12
F6 29.54 ± 0.06 0.404 ± 0.04
F7 27.82 ± 0.05 0.415 ± 0.06
F8 27.16 ± 0.18 0.435 ± 0.12
F9 30.78 ± 0.06 0.421 ± 0.08
F10 28.45 ± 0.12 0.408 ± 0.05
F11 29.65 ± 0.05 0.416 ± 0.14
F12 31.24 ± 0.11 0.4123 ± 0.02
a (q ± S.D) n ¼ 3.
Table 3 e Post-compression evaluation.
Formulation
code
Hardness
(kg/cm2 ± SD)a
Thickness
(mm ± SD)a
F1 3.10 ± 0.10 3.24 ± 0.005
F2 5.06 ± 0.15 3.33 ± 0.026
F3 2.11 ± 0.12 3.43 ± 0.015
F4 3.46 ± 0.05 3.24 ± 0.011
F5 7.23 ± 0.05 3.43 ± 0.020
F6 2.36 ± 0.11 3.16 ± 0.015
F7 4.38 ± 0.02 3.55 ± 0.005
F8 8.53 ± 0.07 3.36 ± 0.015
F9 2.63 ± 0.05 3.24 ± 0.015
F10 3.11 ± 0.07 3.27 ± 0.005
F11 7.13 ± 0.11 3.58 ± 0.010
F12 2.0 ± 0.10 3.26 ± 0.020
a n ¼ 10.
b n ¼ 20.bindings among the polymeric chains and form a thick gel
layer at the tablet surface, which gets eroded over a period of
time. These parameters are responsible for controlling drug
release rate from HPMC tablets (Costa and Lobo, 2001).Tapped density
(g/ml)
Compressibility
index (%)
Hausner's
ratio
0.434 ± 0.11 5.99 ± 0.04 1.06 ± 0.13
0.439 ± 0.08 7.97 ± 0.17 1.08 ± 0.08
0.449 ± 0.13 7.34 ± 0.09 1.07 ± 0.02
0.444 ± 0.03 8.10 ± 0.08 1.08 ± 0.15
0.464 ± 0.09 9.05 ± 0.11 1.09 ± 0.06
0.449 ± 0.16 10.02 ± 0.06 1.11 ± 0.12
0.444 ± 0.11 6.53 ± 0.15 1.06 ± 0.04
0.478 ± 0.09 8.99 ± 0.02 1.09 ± 0.11
0.484 ± 0.07 13.01 ± 0.14 1.14 ± 0.03
0.439 ± 0.05 7.06 ± 0.07 1.07 ± 0.08
0.454 ± 0.08 8.37 ± 0.18 1.09 ± 0.05
0.492 ± 0.12 16.19 ± 0.07 1.19 ± 0.12
Wt. variation
(mg ± SD)b
Friability
(%w/w)b
Drug content
(% ± SD)a
314.65þ_2.37 0.58 ± 0.06 99.2 ± 0.14
314.10 ± 2.06 0.64 ± 0.11 98.6 ± 0.12
315.55 ± 2.52 0.48 ± 0.02 100.5 ± 0.09
316.00 ± 2.62 0.78 ± 0.05 98.6 ± 0.05
315.30 ± 2.26 0.54 ± 0.02 99.8 ± 0.12
315.40 ± 1.89 0.67 ± 0.12 98.5 ± 0.02
316.20 ± 1.75 0.54 ± 0.07 97.8 ± 0.05
315.33 ± 2.36 0.45 ± 0.11 101.2 ± 0.15
314.05 ± 1.25 0.64 ± 0.05 99.4 ± 0.08
315.1 ± 2.33 0.72 ± 0.07 97.3 ± 0.15
313.9 ± 1.66 0.59 ± 0.13 102.1 ± 0.08
314.4 ± 2.06 0.68 ± 0.02 99.3 ± 0.12
Table 4 e Post-compression evaluation.
Formulation
code
FLT (sec ± SD)a FD (h) SI (% ± SD)a
F1 28 ± 2.2 >24 91.36 ± 0.34
F2 24 ± 2.8 >24 88.8 ± 0.28
F3 26 ± 3.1 <24 90.4 ± 0.38
F4 32 ± 2.4 >24 80.8 ± 0.4
F5 28 ± 2.5 >24 83.04 ± 0.26
F6 38 ± 3.2 <24 81.44 ± 0.42
F7 62 ± 2.7 >24 44.16 ± 0.33
F8 55 ± 2.5 >24 53.92 ± 0.38
F9 69 ± 2.8 >24 47.52 ± 0.42
F10 98 ± 3.2 <24 31.8 ± 0.25
F11 72 ± 3.4 <24 30.56 ± 0.42
F12 104 ± 3.1 <24 34.4 ± 0.28
a n ¼ 3, FD e floating duration, FLT e floating lag time.
Fig. 11 e In vitro drug release profiles of formulations
F8eF12 and marketed formulation.
Fig. 12 e In vitro drug release profile of optimized and
marketed formulation.
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granulation could be due to the formation of a more uniform,
and hence, a more effective and rigid hydrophobic coating
around the hydrophilic drug particles during hot melt granu-
lation (Nanjwade et al., 2011). The decrease in drug release
rate when the hydrophobic content of the matrix was
increased may be due to slower penetration of the dissolution
medium in matrices as a result of increased lipophilicity
(Hamdani et al., 2002). Further, penetration of dissolution fluid
was hindered by the hydrophobic coating around the drug
particles, leading to diminished drug release over an extended
period (Yonezava et al., 2001).
3.3. Physical characteristics
The granules of twelve formulations (F1eF12) were evaluated
for angle of repose, bulk density, tapped density, Carr's index
and Hausner's ratio showed the pre-compressed blend has
good flow property (Table 2). Formulated matrix tablets evalu-
ated for physical parameters such as hardness, thickness,
weight variation, friability, drug content and swelling index, the
results are shown in Table 3. It was found that all the granules
have good flow property as they showed angle of repose value
was between 25 and 30, represents good flow property. Carr's
index value was found to be less than 10 showing excellent
property except formulation F9 and F12 which showed 13.04
and 16.19 respectively. Hausner's ratio was found to be lessFig. 10 e In vitro drug release profiles of formulations
F1eF7.than 1.12 showing excellent flow property except formulation
F9 and F12 which showed 1.14 and 1.19 respectively.
The total weight of each formulation was maintained
constant; the weight variations of the tablets were within the
permissible limits. According to IP specification, for tablets
weighing more than 250 mg, ±5% deviation from the mean
weight is acceptable. The weight of the tablet was fixed at
312.5 mg and was maintained for all the batches in order to
minimize the effect of weight on the drug release because the
effect of retardant/polymer concentration is the only area of
interest. Tablet hardness varied as hydrophobic retardantwas
changed. Hardness of tablets containing hydrogenated cot-
tonseed oil was in range 3e4.4 kg/cm2 (approx.) while that ofTable 5 e Showing f1 and f2 values.
Formulation code f1 Value f2 Value
F1 9 62
F2 14 56
F3 8 64
F4 15 54
F5 20 47
F6 13 57
F7 14 54
F8 6 68
F9 14 54
F10 39 34
F11 37 31
F12 62 21
Table 6 e Independent t-test values for comparison
between F8 and marketed product.
Time points (h) t-Statistic dF Two-tailed
probability (p)
1 4.53 10 0.0011
2 2.03 10 0.0693
3 0.46 10 0.6551
4 16.84 10 0.0000
6 16.92 10 0.0000
8 5.47 10 0.0003
10 3.62 10 0.0046
12 1.707 10 0.1187
16 5.559 10 0.0002
20 1.755 10 0.1098
24 1.112 10 0.2923
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(approx.) and cetyl alcohol showed hardness in range
2e2.6 kg/cm2 (approx.). Tablet thickness was also used to
assess the quality of tablets. The thickness of floating tablets
ranged from 3.16 to 3.58 mm. Friability test of all the formu-
lations was found satisfactory showing enough resistance to
themechanical shock and abrasion less than 1%. Drug content
in all formulations was calculated and the presence of active
ingredient ranged from 97 to 102%.
Swelling studywas donewhich indicated that therewas no
significant swelling. All formulations showed swelling only up
to first 4 h due to the presence of hydrophilic polymer (Table
4), and then constant results were obtained.3.4. Evaluation of buoyancy of the tablets
The in vitro buoyancy studies in 0.1 N HCl (pH 1.2), revealed
buoyancy variations for all the formulations (Table 4). SodiumFig. 13 e Kinetic evaluation of optimized formulation (F8): (a) ze
KorsmeyerePeppas plot.bicarbonate was used as the effervescent base which gener-
ates carbon-di-oxide gas in the presence of hydrochloric acid
present in dissolution medium. The gas generated is trapped
and protectedwithin the gel (formed by hydration of Methocel
K15 M), thus decreasing the density of the tablet. As the
density of the tablet falls below 1 (density of water), the tablet
becomes buoyant. Preliminary studies were done to estimate
the ideal amount of the effervescent base needed to obtain
short floating lag time togetherwith prolonged buoyancy. This
revealed that sodium bicarbonate in the amount 50 mg pro-
duced tablets with lag time less than aminute in formulations
F1eF6 and F8 and more than 1 but less than 2 min in formu-
lations F7 and F9eF12. It was found that the tablets of for-
mulations F1, F2, F4, F5 and F7eF9 floated in buffer for
durationmore than 24 h and tablets of formulations F3, F6 and
F10eF12 floated in the buffer solution for less than 24 h. The
formulations containing carnauba wax showed superiority in
floating duration as well as maintained the integrity of for-
mulations due to comparatively more hardness than other
formulations. Although the specific gravity of cetyl alcohol is
least (0.8187 at 50 C), that of hydrogenated cottonseed oil is
lesser (0.917 at 25 C) and that of carnauba wax was highest
(0.990e0.999 at 25 C) among three, but due to comparatively
more hardness of carnauba wax it had prolonged duration of
floating along with integrity.
3.5. In vitro drug release
In vitro dissolution studies were performed in 0.1 N HCl (1.2
pH) and results depicted in Figs. 10 and 11. Formulations F7, F8
and F9 showed release for 24 h up to 99.62, 99.9 and 98.75%
respectively. Marketed tablet showed 99.54% release in 24 h.
Formulations F1, F2, F3, F4 and F6 showed release less than
24 h. F1, F2 and F3 formulations each had hydrophobicro order plot, (b) first order plot, (c) Higuchi plot, (d)
Table 7 e Stability studies of optimized formulation (F8).
Parameters After
30 days
After
60 days
After
90 days
Physical appearance No change No change No change
Weight variation
(mg ± SD)b
315.33 ± 2.36 315.28 ± 2.1 314.86 ± 1.94
Thickness (mm ± SD)a 3.36 ± 0.015 3.38 ± 0.021 3.42 ± 0.026
Hardness
(kg/cm2 ± SD)a
8.53 ± 0.07 8.53 ± 0.11 8.64 ± 0.23
Friability (% ± SD)b 0.45 ± 0.11 0.45 ± 0.08 0.45 ± 0.14
Drug content (%)a 101.2 ± 0.15 101.12 ± 0.32 100.96 ± 0.21
Buoyancy lag time
(sec ± SD)c
55 ± 2.5 56 ± 2.9 56 ± 3.2
Duration of
floating (h)
>24 >24 >24
a n ¼ 10.
b n ¼ 20.
c n ¼ 3.
b e n i - s u e f u n i v e r s i t y j o u r n a l o f b a s i c a n d a p p l i e d s c i e n c e s 3 ( 2 0 1 4 ) 1 2 2e1 3 2 131retardant in concentration 80 mg which is less so, sustained
effect was less. Formulations F4 and F6 also showed less
sustained effect while formulation F5 showed release more
than 24 h as an exception because even if concentration was
120 mg (lesser) the sustained effect was more may be due to
combination of hydrophilic polymer and hydrophobic retar-
dant (i.e. carnauba wax), which showed good effect even in
less concentration. Hydrophilic polymer was used as sus-
taining agent, gas (carbon-di-oxide) entrapping agent and also
as filler.
Formulations F10, F11 and F12 failed to show sustained
effectmay be due to less concentration of hydrophilic polymer
and thus unable to form good matrix. All the three retardants
in concentration of 160 mg, in formulations F7, F8 and F9
showed desired release for 24 h but after comparing with
marketed formulation (VENTAB-XL 37.5), it was found
formulation F8 was most similar to it and hence formulation
F8 was considered as optimized formulation (Fig. 12). The
similarity and dissimilarity factor comparison is showed in
Table 5. Independent t-test (Table 6) also proved that F8 was
the best formulation as the maximum time points of F8 had
p > 0.05 (i.e. retaining the Null's hypothesis) compared to other
formulations proving that it is most similar to marketedTable 8 e Kinetic studies of formulations F1eF12
Formulation Zero order First order Higu
R2 R2 R2
F1 0.9827 0.8366 0.99
F2 0.9923 0.8344 0.97
F3 0.9748 0.9272 0.99
F4 0.991 0.7314 0.95
F5 0.9925 0.7918 0.98
F6 0.9671 0.9025 0.98
F7 0.9924 0.7335 0.97
F8 0.9669 0.8098 0.99
F9 0.9878 0.8434 0.98
F10 0.8293 0.9215 0.93
F11 0.9031 0.9474 0.96
F12 0.9573 0.8908 0.96product. The amount of hydrophobic retardant was found to
be inversely proportional to rate of release. Cetyl alcohol
showed good results, hydrogenated cottonseed oil showed
better results and carnauba wax showed best results (Fig. 13).
Hardness also played an important role in release. For-
mulations F8 had the higher hardness value and hence
showed good sustained property. Formulations made with
cetyl alcohol i.e. F3, F6, F9 and F12 had least hardness and thus
had less sustained effect compared to other formulations. But
as an exception F9 showed release up to 24 h, thus it can be
concluded that cetyl alcohol also shows good release in the
concentration 160 mg. Hardness obtained with tablets of
carnauba wax was higher whereas with hydrogenated cot-
tonseed oil it was moderate and cetyl alcohol tablets showed
least hardness.3.6. Stability studies
According to ICH guidelines, three months stability studies
conducted at controlled temperature 40 C ± 2 C and hu-
midity 75 ± 5% RH showed negligible changes in results (Table
7).3.7. Kinetic analysis of release data
To understand the rate and mechanism of drug release from
optimized tablet formulation, dissolution data was fitted into
different release kineticmodels. Themodel that best fitted the
release data was selected based on the correlation coefficient
value (r2) obtained from various kinetic models (Table 8).
In vitro drug release profile from all these formulations could
be best expressed by KorsmeyerePeppas equation and Higu-
chi equations as plots showed highest linearity with r2 value
0.9164e0.9961 and 0.9805e0.9982 respectively. In Kors-
meyerePeppas equation, linear plot was for optimized
formulation with high correlation coefficient (r2) value 0.9923
and Higuchi value 0.9982. Also, KorsmeyerePeppas equation's
‘n’ values for all formulations except F12were above 0.5. It was
concluded that the optimized formulation followed mixed
mechanism of diffusion and erosion, so called anomalous/
Non-Fickian diffusion mechanism for drug release.chi KorsmeyerePeppas Release
mechanismR2 n
22 0.9902 0.614 Non-Fickian
0.973 0.5624 Non-Fickian
68 0.9961 0.5395 Non-Fickian
95 0.966 0.544 Non-Fickian
05 0.992 0.6961 Non-Fickian
51 0.9778 0.6685 Non-Fickian
36 0.9809 0.5651 Non-Fickian
82 0.9923 0.6448 Non-Fickian
22 0.9848 0.6711 Non-Fickian
52 0.9164 0.63 Non-Fickian
59 0.9638 0.849 Non-Fickian
60 0.9642 0.2616 Fickian
b e n i - s u e f un i v e r s i t y j o u rn a l o f b a s i c a n d a p p l i e d s c i e n c e s 3 ( 2 0 1 4 ) 1 2 2e1 3 21324. Conclusion
The effervescent-based floating drug delivery system was the
promising system. The use of hydrophobic retardant and hy-
drophilic polymer in combination had its own advantages of
maintaining integrity and buoyancy of tablets. And also in
initial burst effect was minimized. It could be concluded that
for proper floating duration and in vitro release, the hydro-
phobic retardant and hydrophilic polymer must be used in
proper ratio. Formulation F8 showed release similar to mar-
keted tablet and was considered optimized formulation. F8
followed zero order, Higuchi and KorsmeyerePeppas release
kinetics. The aim of preparation of gastroretentive tablets of
Venlafaxine HCl was achieved.
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